Logo

American Heart Association

  11
  0


Final ID: MP703

Right Ventricular Dysfunction Strongly Predicts Thromboembolism and Major Bleeding in Tetralogy of Fallot and Pulmonary Atresia with Intact Ventricular Septum

Abstract Body (Do not enter title and authors here): Introduction
Complex congenital heart disease (CHD) patients with atrial arrhythmias have higher rates of morbidity and mortality compared to less complex CHD patients. This study aims to identify echocardiographic predictors of thromboembolism (TE) and major bleeding in patients with Tetralogy of Fallot (ToF) or Pulmonary Atresia with Intact Ventricular Septum (PA-IVS) and atrial fibrillation or flutter (AF).
Methods
This cohort study included patients with ToF or PA-IVS who had a diagnosis of AF who underwent a TTE across three sites. Outcomes were incidence rate of major bleeding or TE, calculated using univariable and multivariable cox regression with interaction for anticoagulant choice and fractional area change (FAC). The HAS-BLED score was augmented with major predictors of bleeding, and receiver operator curves compared.
Results
We included 300 patients (287 ToF [95.7%], 13 PA-IVS [4.3%]), mean age 45.6 years. Most received warfarin (227 [79.4%]), 40 (13%) used DOACs, and 5 (1.6%) used enoxaparin. TTE predictors of TE included large LVOT diameter ≥3cm (HR 8.92, p=0.002), small LVOT VTI (p=0.014), FAC <30% (HR 7.08, p=0.026) and moderate RV dysfunction (HR 10.75, p=0.026). Predictors of major bleeding included moderate tricuspid regurgitation (HR 2.40, p=0.022), right atrial pressure (1.12, p<0.001), severe RA enlargement (HR 2.30, p=0.048), RV mid diameter (HR 1.06, p=0.005), RV end diastolic area (HR 1.04, p=0.021), RV end systolic area (HR 1.05, p=0.016) elevated RVSP and FAC ≤45% (HR 0.37, p=0.016).
Among warfarin users, impaired RV function (FAC ≤45%) was linked to reduced major bleeding events (HR 0.27, p=0.025). There was a nonsignificant trend towards higher bleeding in DOAC users with FAC >45% (HR 3.87, p=0.284), but significantly higher bleeding in DOAC users with FAC ≤45% (HR 12.41, p=0.008) vs. warfarin users with normal RV function (table 1).
We developed an augmented HAS-BLED score: the standard score plus one point for moderate-to-severe pulmonic or tricuspid regurgitation and one for FAC ≤45%. This outperformed the standard HAS-BLED in predicting major bleeding (AUC 0.67 augmented vs. 0.57 un-augmented, p=0.008) (figure 1).
Conclusion
Echocardiographic evidence of right heart disease is a strong predictor of major bleeding in patients with ToF or PA-IVS. FAC is a useful tool to determine excess major bleeding risk, particularly in DOAC users. Augmenting HAS-BLED with right heart parameters improves diagnostic accuracy.
  • O'shea, Michael  ( Mayo Clinic , Phoenix , Arizona , United States )
  • Green, Dani  ( Mayo Clinic , Phoenix , Arizona , United States )
  • Alozie, Nneoma  ( Mayo Clinic , Phoenix , Arizona , United States )
  • Marshall, Chelsea  ( Mayo Clinic , Phoenix , Arizona , United States )
  • Egbe, Alexander  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Connolly, Heidi  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Girardo, Marlene  ( Mayo Clinic , Phoenix , Arizona , United States )
  • El Masry, Hicham  ( Mayo Clinic , Phoenix , Arizona , United States )
  • Majdalany, David  ( Mayo Clinic , Phoenix , Arizona , United States )
  • Arunachalam Karikalan, Suganya  ( Mayo Clinic , Phoenix , Arizona , United States )
  • Ravi, Srekar  ( Mayo Clinic , Phoenix , Arizona , United States )
  • Van Ligten, Matthew  ( Mayo Clinic , Phoenix , Arizona , United States )
  • Bacon, Adam  ( Mayo Clinic , Phoenix , Arizona , United States )
  • Habib, Eiad  ( Mayo Clinic , Phoenix , Arizona , United States )
  • Baqal, Omar  ( Mayo Clinic , Phoenix , Arizona , United States )
  • Smyth, Philip  ( Mayo Clinic , Phoenix , Arizona , United States )
  • Wang, Winston  ( Mayo Clinic , Phoenix , Arizona , United States )
  • Author Disclosures:
    Michael O'Shea: DO have relevant financial relationships ; Individual Stocks/Stock Options:Vertex Pharmaceuticals Inc:Active (exists now) | Danielle (Dani) Green: DO NOT have relevant financial relationships | Nneoma Alozie: No Answer | Chelsea Marshall: No Answer | Alexander Egbe: No Answer | Heidi Connolly: DO NOT have relevant financial relationships | Marlene Girardo: No Answer | Hicham El Masry: No Answer | David Majdalany: DO NOT have relevant financial relationships | Suganya Arunachalam Karikalan: No Answer | Srekar Ravi: No Answer | Matthew van Ligten: No Answer | Adam Bacon: No Answer | Eiad Habib: DO NOT have relevant financial relationships | Omar Baqal: DO NOT have relevant financial relationships | Philip Smyth: DO NOT have relevant financial relationships | Winston Wang: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Adult Congenital Heart Disease Across the Lifespan

Saturday, 11/08/2025 , 09:15AM - 10:30AM

Moderated Digital Poster Session

More abstracts on this topic:
Cardiac Magnetic Resonance Imaging in Tetrology of Fallot Patients and Relationship to Obesity

Dusza Patrick, Tran Andrew, Hor Kan


4-5 Years Outcomes of Left Atrial Appendage Closure vs. Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis:

Khan Muhammad Aslam, Haider Taimoor, Bhattarai Shraddha, Afzal Hafsa, Khan Bilal, Muhammad Anza, Shafique Nouman, Bhatia Hitesh, Aafreen Asna, Adil Abid Nawaz Khan, Akbar Usman, Khan Alamzaib, Haider Muhammad Adnan

More abstracts from these authors:
Septal Thickness has a Variable Effect on Shock Incidence Rate by ICD Indication in Hypertrophic Cardiomyopathy.

O'shea Michael, Ravi Srekar, Baqal Omar, Fatunde Bade, Alsidawi Said

Incidence and Associations of Normal QRS vs Right Bundle Branch Block in Ebstein's Anomaly

Havangi Prakash Shisheer, Poddar Aastha, Connolly Heidi, Egbe Alexander, Madhavan Malini

You have to be authorized to contact abstract author. Please, Login
Not Available